ClinicalTrials.gg
CompletedNCT01882439OPAL BEYONDUpdated Sep 15, 2017Results posted

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

A Phase 3 interventional study of Tofacitinib and Tofacitinib in Psoriatic Arthritis, sponsored by Pfizer. Completed at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.

Enrollment
4th of 10
395 · median 237
Started
2013
the only one that year
Phase 3
7 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
5 of 10
Pfizer

Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tofacitinib in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • psoriatic arthritis
  • tofacitinib
  • ACR20
  • HAQ-DI
  • TNF inhibitor failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
  • Active plaque psoriasis at screening
  • Inadequate efficacy or lack of toleration to previously administered TNF inhibitor

Exclusion criteria

Exclusion Criteria:

  • Non-plaque forms of psoriasis (with exception of nail psoriasis)
  • History of rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Treatment Sequence A

    Tofacitinib 5 mg BID for 6 months

    Drug: Tofacitinib

  • Experimental
    Treatment Sequence B

    Tofacitinib 10 mg BID for 6 months

    Drug: Tofacitinib

  • Placebo comparator
    Treatment Sequence C

    Placebo for 3 months then tofacitinib 5 mg BID for 3 months

    Other: Placebo · Drug: Tofacitinib

  • Placebo comparator
    Treatment Sequence D

    Placebo for 3 months then tofacitinib 10 mg BID for 3 months

    Other: Placebo · Drug: Tofacitinib

Interventions

  • tablets, 5 mg BID x 6 months

  • tablets, 10 mg BID x 6 months

  • OtherPlacebo

    tablets, to match tofacitinib 5 mg BID x 3 months

  • tablets, 5 mg BID x 3 months

  • OtherPlacebo

    tablets, to match tofacitinib 10 mg BID x 3 months

  • tablets, 10 mg BID x 3 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).

    Time frame: Month 3

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3

    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.

    Time frame: Month 3

Secondary outcomes

  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6

    ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Time frame: Week 2 and Months 1, 2, 3, 4, and 6

  2. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6

    ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Time frame: Week 2 and Months 1, 2, 3, 4, and 6

  3. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6

    ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Time frame: Week 2 and Months 1, 2, 4, and 6

  4. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6

    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit.

    Time frame: Week 2 and Months 1, 2, 4, and 6

  5. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Month 3

  6. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3

    Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

    Time frame: Month 3

  7. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

    Time frame: Month 3

  8. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3

    The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

    Time frame: Month 3

  9. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3

    Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

    Time frame: Month 3

  10. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3

    Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

    Time frame: Month 3

  11. Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6

    The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders.

    Time frame: Week 2, Months 1, 2, 3, 4, and 6

  12. Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6

    The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, and 6

  13. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6

    PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders.

    Time frame: Months 1, 3, and 6

  14. Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6

    Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, and 6

  15. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6

    The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, and 6

  16. Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6

    Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, and 6

  17. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  18. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  19. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represent levels \& kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  20. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  21. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  22. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  23. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  24. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  25. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  26. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  27. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  28. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  29. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  30. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  31. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  32. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  33. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  34. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  35. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

  36. Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6

    BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit.

    Time frame: Months 1, 3, 6

07

Results

Posted Sep 15, 2017

Participant flow

Data through End of Study (Month 6)

Participant flow — Overall Study
MilestoneTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Started1311326665
Completed1221115656
Not completed921109
Withdrew: Adverse event related to study drug3812
Withdrew: Pregnancy0100
Withdrew: Protocol violation2201
Withdrew: No longer willing to participate1423
Withdrew: Medication error with no associated ae0020
Withdrew: Insufficient clinical response1442
Withdrew: Adverse event unrelated to study drug2211

Outcome measures

PrimaryPercentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3

ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).

Time frame:
Month 3
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 349.62 (14.72 to 37.19)46.97 (12.10 to 34.51)23.66 (-14.72 to 9.43)
Statistical analysis
  • Tofacitinib, 5 mg Twice Daily vs Placebo · Large sample approximation · p = <0.0001 · Risk difference (rd): 25.95 · 95% CI 14.72 to 37.19Missing response (MR) = non-response (NR)
  • Tofacitinib, 10 mg, Twice Daily vs Placebo · Large sample approximation · p = <0.0001 · Risk difference (rd): 23.31 · 95% CI 12.10 to 34.51MR=NR
PrimaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3

The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.

Time frame:
Month 3
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3-0.3920 ± 0.04544-0.3540 ± 0.04579-0.1391 ± 0.04573
Statistical analysis
  • Tofacitinib, 5 mg Twice Daily vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -0.2529 · 95% CI -0.3792 to -0.1266No imputation
  • Tofacitinib, 10 mg, Twice Daily vs Placebo · Mixed Models Analysis · p = 0.0009 · Mean difference (net): -0.2150 · 95% CI -0.3419 to -0.0881No imputation
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6

ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

Time frame:
Week 2 and Months 1, 2, 3, 4, and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=8,13,NA,NA,4)6.119.85NANA3.05
Month 1 (n=23,14,NA,NA,8)17.5610.61NANA6.11
Month 2 (n=33,30,NA,NA,14)25.1922.73NANA10.69
Month 3 (n=39,37,NA,NA,19)29.7728.03NANA14.50
Month 4 (n=50,38,15,21,NA)38.1728.7922.7332.31NA
Month 6 (n=50,39,21,23,NA)38.1729.5531.8235.38NA
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6

ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

Time frame:
Week 2 and Months 1, 2, 3, 4, and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=2,3,NA,NA,1)1.532.27NANA0.76
Month 1 (n=7,5,NA,NA,3)5.343.79NANA2.29
Month 2 (n=17,13,NA,NA,6)12.989.85NANA4.58
Month 3 (n=22,19,NA,NA,13)16.7914.39NANA9.92
Month 4 (n=24,20,6,14,NA)18.3215.159.0921.54NA
Month 6 (n=28,19,10,12,NA)21.3714.3915.1518.46NA
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6

ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

Time frame:
Week 2 and Months 1, 2, 4, and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=35,38,NA,NA,17)26.7228.79NANA12.98
Month 1 (n=45,56,NA,NA,29)34.3542.42NANA22.14
Month 2 (n=63,63,NA,NA,34)48.0947.73NANA25.95
Month 4 (n=78,69,30,33,NA)59.5452.2745.4550.77NA
Month 6 (n=78,65,33,35,NA)59.5449.2450.0053.85NA
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6

The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit.

Time frame:
Week 2 and Months 1, 2, 4, and 6
Reported as:
Least squares mean · Units on scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6
Units on scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (129,130,NA,NA,128)-0.2198 ± 0.03145-0.1652 ± 0.03160NA ± NANA ± NA-0.0655 ± 0.03133
Month 1 (128,129,NA,NA,130)-0.3229 ± 0.04074-0.2279 ± 0.04073NA ± NANA ± NA-0.1481 ± 0.04038
Month 2 (125,126,NA,NA,121)-0.4114 ± 0.04311-0.3131 ± 0.04316NA ± NANA ± NA-0.1620 ± 0.04317
Month 4 (125,121,57,58,NA)-0.4455 ± 0.04489-0.3305 ± 0.04523-0.3836 ± 0.06443-0.3918 ± 0.06418NA ± NA
Month 6 (122,112,56,56,NA)-0.4365 ± 0.04642-0.3397 ± 0.04720-0.4808 ± 0.06680-0.4157 ± 0.06665NA ± NA
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Month 3
Reported as:
Least squares mean · mg/L
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3
mg/LTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3-5.4657 ± 1.80096-5.9156 ± 1.831811.0233 ± 1.82879
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3

Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

Time frame:
Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3
mmTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3-21.66 ± 2.162-20.88 ± 2.188-7.72 ± 2.184
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3

Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

Time frame:
Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3
mmTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3-21.59 ± 2.228-19.88 ± 2.248-7.14 ± 2.247
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3

The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

Time frame:
Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3
mmTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3-27.25 ± 1.893-28.95 ± 1.916-15.88 ± 1.929
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3

Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

Time frame:
Month 3
Reported as:
Least squares mean · Joints
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3
JointsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3-7.6 ± 0.59-6.7 ± 0.60-2.7 ± 0.60
SecondaryChange From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3

Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

Time frame:
Month 3
Reported as:
Least squares mean · Joints
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3
JointsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3-9.9 ± 0.97-9.7 ± 0.98-4.5 ± 0.98
SecondaryPercentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6

The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders.

Time frame:
Week 2, Months 1, 2, 3, 4, and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=43,45,NA,NA,23)32.8234.09NANA17.56
Month 1 (n=56,66,NA,NA,45)42.7550.00NANA34.35
Month 2 (n=67,72,NA,NA,43)51.1554.55NANA32.82
Month 3 (n=77,64,NA,NA,38)58.7848.48NANA29.01
Month 4 (n=74,75,34,38.NA)56.4956.8251.5258.46NA
Month 6 (n=77,68,34,36,NA)58.7851.5251.5255.38NA
SecondaryChange From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6

The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, and 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=120,122,NA,NA,125)-0.5 ± 0.07-0.8 ± 0.07NA ± NANA ± NA-0.2 ± 0.07
Month 3 (n=112,116,NA,NA,112)-0.7 ± 0.08-1.1 ± 0.08NA ± NANA ± NA-0.4 ± 0.08
Month 6 (n=116,108,55,51,NA)-0.9 ± 0.08-1.1 ± 0.09-1.0 ± 0.12-1.0 ± 0.13NA ± NA
SecondaryPercentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6

PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders.

Time frame:
Months 1, 3, and 6
Reported as:
Number · Percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6
Percentage of participantsTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=12,15,NA,NA,5)15.0018.52NANA5.81
Month 3 (n=17,35,NA,NA,12)21.2543.21NANA13.95
Month 6 (n=27,37,11,14,NA)33.7545.6826.1931.82NA
SecondaryChange From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6

Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, and 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=65,64,NA,NA,62)-2.8 ± 0.63-4.0 ± 0.65NA ± NANA ± NA-1.1 ± 0.64
Month 3 (n=64,58,NA,NA,55)-5.2 ± 0.73-5.4 ± 0.78NA ± NANA ± NA-1.9 ± 0.78
Month 6 (n=61,55,25,26,NA)-6.0 ± 0.84-6.0 ± 0.90-5.4 ± 1.33-5.2 ± 1.26NA ± NA
SecondaryChange From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6

The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, and 6
Reported as:
Least squares mean · Units of scale
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6
Units of scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=94,104,NA,NA,98)-1.9 ± 0.31-1.9 ± 0.30NA ± NANA ± NA-1.0 ± 0.30
Month 3 (n=92,96,NA,NA,87)-2.5 ± 0.34-2.8 ± 0.33NA ± NANA ± NA-1.3 ± 0.34
Month 6 (n=91,93,40,43,NA)-2.6 ± 0.36-3.1 ± 0.35-2.6 ± 0.53-2.4 ± 0.51NA ± NA
SecondaryChange From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6

Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, and 6
Reported as:
Least squares mean · Units of scale
Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6
Units of scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=82,95,NA,NA,91)-1.0 ± 0.19-0.8 ± 0.18NA ± NANA ± NA-0.5 ± 0.18
Month 3 (n=79,86,NA,NA,82)-1.3 ± 0.19-1.3 ± 0.18NA ± NANA ± NA-0.5 ± 0.19
Month 6 (n=77,84,38,41,NA)-1.5 ± 0.19-1.6 ± 0.18-1.4 ± 0.26-1.3 ± 0.26NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=124,127,NA,NA,129)4.65 ± 0.5433.98 ± 0.542NA ± NANA ± NA1.70 ± 0.534
Month 3 (n=121,120,NA,NA,117)5.18 ± 0.6845.34 ± 0.687NA ± NANA ± NA1.77 ± 0.689
Month 6 (n=118,110,56,56,NA)5.71 ± 0.7515.00 ± 0.7686.45 ± 1.0766.98 ± 1.074NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=124,127,NA,NA,129)4.09 ± 0.7404.19 ± 0.738NA ± NANA ± NA2.33 ± 0.725
Month 3 (n=121,120,NA,NA,117)4.94 ± 0.8754.28 ± 0.879NA ± NANA ± NA2.97 ± 0.880
Month 6 (n=118,110,56,56,NA)5.36 ± 0.8785.37 ± 0.9025.37 ± 1.2656.47 ± 1.259NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6

SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represent levels \& kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,129,NA,NA,129)3.97 ± 0.5833.10 ± 0.587NA ± NANA ± NA1.55 ± 0.580
Month 3 (n=124,120,NA,NA,117)5.00 ± 0.7214.08 ± 0.732NA ± NANA ± NA1.69 ± 0.734
Month 6 (n=121,112,56,56,NA)5.39 ± 0.7953.88 ± 0.8185.89 ± 1.1535.60 ± 1.149NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6

SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=126,128,NA,NA,129)4.22 ± 0.6303.55 ± 0.633NA ± NANA ± NA2.24 ± 0.623
Month 3 (n=122,120,NA,NA,117)4.99 ± 0.8055.44 ± 0.814NA ± NANA ± NA2.85 ± 0.814
Month 6 (n=120,112,56,56,NA)5.58 ± 0.8575.24 ± 0.8817.01 ± 1.2417.21 ± 1.239NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=127,128,NA,NA,129)6.86 ± 0.6346.39 ± 0.638NA ± NANA ± NA2.31 ± 0.633
Month 3 (n=124,120,NA,NA,117)7.00 ± 0.7867.59 ± 0.799NA ± NANA ± NA2.10 ± 0.804
Month 6 (n=121,112,56,56,NA)7.60 ± 0.8487.69 ± 0.8768.15 ± 1.23410.48 ± 1.236NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)3.24 ± 0.5293.74 ± 0.535NA ± NANA ± NA2.29 ± 0.527
Month 3 (n=124,120,NA,NA,117)3.67 ± 0.6393.92 ± 0.651NA ± NANA ± NA2.45 ± 0.651
Month 6 (n=121,111,56,56,NA)3.88 ± 0.6954.46 ± 0.7196.00 ± 1.0105.34 ± 1.010NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)4.52 ± 0.6784.30 ± 0.684NA ± NANA ± NA1.73 ± 0.674
Month 3 (n=124,120,NA,NA,117)4.95 ± 0.8284.75 ± 0.842NA ± NANA ± NA2.41 ± 0.843
Month 6 (n=122,111,56,56,NA)5.94 ± 0.8595.15 ± 0.8945.75 ± 1.2567.06 ± 1.256NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,129,NA,NA,129)4.93 ± 0.7484.92 ± 0.754NA ± NANA ± NA2.33 ± 0.744
Month 3 (n=124,120,NA,NA,117)6.25 ± 0.8445.46 ± 0.861NA ± NANA ± NA2.89 ± 0.861
Month 6 (n=122,112,56,56,NA)5.92 ± 0.8965.58 ± 0.9305.96 ± 1.3097.90 ± 1.305NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=125,128,NA,NA,129)4.44 ± 0.8943.64 ± 0.892NA ± NANA ± NA3.25 ± 0.878
Month 3 (n=121,120,NA,NA,117)5.44 ± 0.9984.84 ± 1.003NA ± NANA ± NA3.85 ± 1.002
Month 6 (n=119,111,56,56,NA)6.17 ± 1.0105.69 ± 1.0407.05 ± 1.4618.00 ± 1.455NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · T-scores
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6
T-scoresTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)3.80 ± 0.7374.41 ± 0.743NA ± NANA ± NA1.73 ± 0.732
Month 3 (n=124,120,NA,NA,117)4.36 ± 0.8524.11 ± 0.867NA ± NANA ± NA2.11 ± 0.868
Month 6 (n=122,112,56,56,NA)4.38 ± 0.8544.98 ± 0.8845.06 ± 1.2455.67 ± 1.241NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)-0.15 ± 0.035-0.10 ± 0.036NA ± NANA ± NA-0.08 ± 0.035
Month 3 (n=124,120,NA,NA,117)-0.17 ± 0.038-0.15 ± 0.039NA ± NANA ± NA-0.05 ± 0.039
Month 6 (n=122,112,56,55,NA)-0.15 ± 0.040-0.15 ± 0.042-0.23 ± 0.059-0.32 ± 0.059NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=127,128,NA,NA,129)-0.11 ± 0.039-0.14 ± 0.039NA ± NANA ± NA-0.03 ± 0.038
Month 3 (n=122,120,NA,NA,117)-0.15 ± 0.039-0.15 ± 0.040NA ± NANA ± NA-0.04 ± 0.039
Month 6 (n=120,112,56,55,NA)-0.19 ± 0.040-0.15 ± 0.042-0.19 ± 0.058-0.17 ± 0.059NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)-0.22 ± 0.039-0.19 ± 0.039NA ± NANA ± NA-0.17 ± 0.039
Month 3 (n=124,120,NA,NA,117)-0.23 ± 0.042-0.22 ± 0.042NA ± NANA ± NA-0.15 ± 0.043
Month 6 (n=122,112,56,55,NA)-0.30 ± 0.047-0.25 ± 0.048-0.39 ± 0.068-0.34 ± 0.068NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)-0.26 ± 0.038-0.25 ± 0.039NA ± NANA ± NA-0.11 ± 0.038
Month 3 (n=124,120,NA,NA,117)-0.32 ± 0.043-0.29 ± 0.044NA ± NANA ± NA-0.12 ± 0.044
Month 6 (n=121,112,56,55,NA)-0.34 ± 0.045-0.31 ± 0.047-0.42 ± 0.066-0.34 ± 0.067NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,128,NA,NA,129)-0.13 ± 0.043-0.21 ± 0.043NA ± NANA ± NA-0.10 ± 0.042
Month 3 (n=124,120,NA,NA,117)-0.19 ± 0.044-0.20 ± 0.045NA ± NANA ± NA-0.12 ± 0.045
Month 6 (n=122,112,56,55,NA)-0.16 ± 0.046-0.20 ± 0.048-0.17 ± 0.068-0.31 ± 0.068NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · mm
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6
mmTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=127,128,NA,NA,128)9.76 ± 1.5659.58 ± 1.574NA ± NANA ± NA3.59 ± 1.557
Month 3 (n=124,119,NA,NA,117)8.62 ± 1.85312.33 ± 1.896NA ± NANA ± NA2.64 ± 1.896
Month 6 (n=122,112,56,55,NA)12.14 ± 1.87012.63 ± 1.94515.68 ± 2.73615.32 ± 2.748NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,129,NA,NA,129)6.0 ± 0.664.4 ± 0.67NA ± NANA ± NA2.2 ± 0.66
Month 3 (n=124,120,NA,NA,117)7.0 ± 0.815.8 ± 0.82NA ± NANA ± NA3.0 ± 0.82
Month 6 (n=122,113,56,56,NA)7.1 ± 0.876.2 ± 0.907.6 ± 1.288.5 ± 1.28NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,129,NA,NA,129)2.7 ± 0.312.3 ± 0.31NA ± NANA ± NA1.0 ± 0.30
Month 3 (n=124,120,NA,NA,117)3.1 ± 0.382.6 ± 0.39NA ± NANA ± NA1.5 ± 0.39
Month 6 (n=122,113,56,56,NA)2.9 ± 0.402.8 ± 0.413.2 ± 0.584.1 ± 0.58NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6
Units on a scaleTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=128,129,NA,NA,129)3.3 ± 0.402.1 ± 0.41NA ± NANA ± NA1.2 ± 0.40
Month 3 (n=124,120,NA,NA,117)3.9 ± 0.483.2 ± 0.49NA ± NANA ± NA1.6 ± 0.49
Month 6 (n=122,113,56,56,NA)4.2 ± 0.523.5 ± 0.544.3 ± 0.764.5 ± 0.76NA ± NA
SecondaryChange From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6

BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit.

Time frame:
Months 1, 3, 6
Reported as:
Least squares mean · cm
Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6
cmTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=26,25,NA,NA,22)-2.04 ± 0.400-1.26 ± 0.412NA ± NANA ± NA-0.34 ± 0.415
Month 3 (n=26,22,NA,NA,19)-2.26 ± 0.465-1.92 ± 0.490NA ± NANA ± NA-1.00 ± 0.506
Month 6 (n=25,22,8,10,NA)-2.02 ± 0.463-1.56 ± 0.489-2.26 ± 0.756-3.05 ± 0.701NA ± NA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib, 5 mg Twice Daily—5/131 (3.8%)49/131 (37.4%)
Tofacitinib, 10 mg, Twice Daily—8/132 (6.1%)48/132 (36.4%)
Placebo/Tofacitinib, 5 mg, Twice Daily—2/66 (3%)19/66 (28.8%)
Placebo/Tofacitinib, 10 mg, Twice Daily—1/65 (1.5%)19/65 (29.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
SyncopeNervous system disorders0/1310/1320/661/65
Atrial flutterCardiac disorders0/1310/1321/660/65
AsthmaRespiratory, thoracic and mediastinal disorders0/1310/1321/660/65
Hypertensive crisisVascular disorders0/1310/1321/660/65
Acute myocardial infarctionCardiac disorders1/1310/1320/660/65
Angina pectorisCardiac disorders1/1310/1320/660/65
Oral candidiasisInfections and infestations1/1310/1320/660/65
PneumoniaInfections and infestations1/1310/1320/660/65
DehydrationMetabolism and nutrition disorders1/1310/1320/660/65
HypotensionVascular disorders1/1310/1320/660/65
Most frequent other events
Most frequent other events
EventTofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Upper respiratory tract infectionInfections and infestations12/1317/1324/667/65
NasopharyngitisInfections and infestations14/13112/1324/661/65
HeadacheNervous system disorders10/13112/1323/664/65
DiarrhoeaGastrointestinal disorders10/1318/1322/662/65
NauseaGastrointestinal disorders5/1317/1325/664/65
HypertensionVascular disorders8/1315/1322/662/65
SinusitisInfections and infestations3/1315/1324/662/65
DizzinessNervous system disorders7/1311/1320/661/65
BronchitisInfections and infestations3/1317/1321/662/65

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Tofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyTotal
Mean49.5 ± 12.351.3 ± 10.948.7 ± 11.249.3 ± 14.050.0 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib, 5 mg Twice DailyTofacitinib, 10 mg, Twice DailyPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyTotal
Female64743842218
Male67582823176
08

Study locations

125 sites
  • Rheumatology Associates P.C.
    Birmingham, Alabama 35205, United States
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801-4414, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Ronald Reagan UCLA Medical Center, Drug Information Center
    Los Angeles, California 90095, United States
  • UCLA David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305, United States
  • New England Research Associates, LLC
    Trumbull, Connecticut 06611, United States
  • Rheumatology Associates of Central Florida, PA
    Orlando, Florida 32806, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc.
    Palm Harbor, Florida 34684, United States
  • Integral Rheumatology & Immunology Specialists (IRIS)
    Plantation, Florida 33324, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • St. Luke's Clinic - Rheumatology
    Boise, Idaho 83702, United States
  • St. Luke's Intermountain Research Center
    Boise, Idaho 83702, United States
  • Bluegrass Community Research, Inc
    Lexington, Kentucky 40504, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • The Center For Rheumatology And Bone Research
    Wheaton, Maryland 20902, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • St. Paul Rheumatology, PA
    Eagan, Minnesota 55121, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Dartmouth-Hitchcock Medical Center (DHMC)
    Lebanon, New Hampshire 03756, United States
  • Cincinnati Rheumatic Disease Study Group, Inc.
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • East Penn Rheumatology Associates, PC
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina 29406, United States
  • Arthritis Clinic
    Jackson, Tennessee 38305, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Adriana M. Pop-Moody, M.D., Clinic, P.A.
    Corpus Christi, Texas 78404, United States
  • Pioneer Research Solutions, Inc.
    Cypress, Texas 77429, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Drug Shipment/Storage: Investigational Drug Services
    Salt Lake City, Utah 84112, United States
  • University of Utah Hospital & Clinics
    Salt Lake City, Utah 84132, United States
  • Dynacare Laboratories
    Seattle, Washington 98122, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Royal Prince Alfred Hospital, Rheumatology Department
    Camperdown, New South Wales 2050, Australia
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research Pty Ltd
    Malvern East, Victoria 3145, Australia
  • Hospital Erasme - Clinique Universitaire de Bruxelles
    Brussels, 1070, Belgium
  • ReumaClinic
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • University Hospital Leuven, Department of Rheumatology
    Leuven, 3000, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • CMIP: Centro Mineiro de Pesquisa Ltda /
    Juiz de Fora, MG 36010-570, Brazil
  • CETAC - DIAGNOSTICO POR IMAGEM (image only)
    Curitiba, PR 80240-160, Brazil
  • EDUMED - Educacao em Saude SS LTDA.
    Curitiba, PR 80440-080, Brazil
  • Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS
    Porto Alegre, RS 90035-003, Brazil
  • Clinica Medica Bonfiglioli Ltda. / Clinica Bonfiglioli
    Campinas, SP 13015-001, Brazil
  • Radiologia Clínica de Campinas - RCC (Images only)
    Campinas, São Paulo 13015-240, Brazil
  • Medical Plus s.r.o.
    Uherske Hradiste, 68601, Czechia
  • Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie
    Corbeil-Essonnes, Cedex 91106, France
  • Hopital Avicenne
    Bobigny, 93000, France
  • Rheumazentrum Prof. Dr. med Gunther Neeck
    Bad Doberan, 18209, Germany
  • Charite Universitatsmedizin Berlin - Campus Charite Mitte
    Berlin, 10117, Germany
  • Rheumapraxis Steglitz
    Berlin, 12161, Germany
  • Schlosspark-Klinik
    Berlin, 14059, Germany
  • Universitaetsklinikum Erlangen, Medizinische Klinik 3
    Erlangen, 91054, Germany
  • CIRI - Centrum für innovative Diagnostik und Therapie Rheumatologie/Immunologie (GmbH)
    Frankfurt am Main, 60528, Germany
  • Medizinische Universitatsklinik Freiburg
    Freiburg, 79106, Germany
  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
    Homburg, 66421, Germany
  • University Hospital of Cologne
    Koeln, 50937, Germany
  • Elisabeth Klinik Bigge
    Olsberg, 59939, Germany
  • Hospital Angeles Clinica Londres
    Mexico City, D.F 06700, Mexico
  • Grupo Medico Camino S.C.
    Mexico City, Distrito Federal 03310, Mexico
  • CLIDITER, S.A. de C.V.
    Mexico, Distrito Federal 06700, Mexico
  • Universidad La Salle AC
    Mexico, Distrito Federal 14000, Mexico
  • Medica Sur, S.A.B. de C.V. (For Emergencies Only)
    Mexico, Distrito Federal 14050, Mexico
  • Centro Integral en Reumatologia SA de CV
    Guadalajara, Jalisco 44160, Mexico
  • Grupo Santa Bernardette S.A. de C.V.
    Guadalajara, Jalisco 44200, Mexico
  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C
    Culiacan, Sinaloa 80000, Mexico
  • Sanatorio CEMSI Chapultepec (For Emergencies Only)
    Culiacan, Sinaloa 80040, Mexico
  • Hospital General de Culiacan "Dr. Bernardo J. Gastelum"
    Culiacan, Sinaloa 80230, Mexico
  • Star Medica S.A. de C.V. (For Emergencies Only)
    Merdia, Yucatan 97133, Mexico
  • Institute Medico Panamericano, S.A. de C.V. (For Emergencies Only)
    Merida, Yucatan 97000, Mexico
  • Unidad Reumatologica Las Americas SCP
    Merida, Yucatan 97000, Mexico
  • Centro de Investigacion Clinica Pensiones
    Merida, Yucatan 97070, Mexico
  • Centro Multidisciplinario para el Desarrollo
    Merida, Yucatan 97130, Mexico
  • Hospital Star Medica Merida (For Emergencies Only)
    Merida, Yucatan 97133, Mexico
  • Christus Muguerza del parque, S.A de C.V
    Chihuahua, 31000, Mexico
  • Investigacion y Biomedicina de Chihuahua
    Chihuahua, 31000, Mexico
  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzez
    Elblag, 82-300, Poland
  • Centrum Radiologii for X-Ray only
    Elblag, 82-300, Poland
  • NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela
    Elblag, 82-300, Poland
  • Wojewodzki Szpital Zespolony Zaklad Radiologii
    Elblag, 82-300, Poland
  • Przychodnia Specjalistyczna Lekarskiej Spozielni Pracy "Medica" for X-Ray Only
    Grodzisk Mazowiecki, 05-825, Poland
  • Specjalistyczne Gabinety Lekarskie "DERMED" Anna Kaszuba
    Lodz, 90-265, Poland
  • NZOZ Lecznica MAK-MED S.C.
    Nadarzyn, 05-830, Poland
  • Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj
    Poznan, 61-397, Poland
  • Reumatika Centrum Reumatologii nzoz
    Warszawa, 02-691, Poland
  • Regional State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a.
    Petrozavodsk, Karelia Republic 185019, Russian Federation
  • State Autonomic Healthcare Institution City Clinical Hospital # 7
    Kazan, Republic of Tatarstan, Russia 420103, Russian Federation
  • SBIH of Moscow "City Clinical Hospital#1 n. a. N.I. Pirogov" of the Healthcare Department of Moscow
    Moscow, 119049, Russian Federation

Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8. PubMed 36076054 ↗
  • Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022 Sep 1;6(1):68. doi: 10.1186/s41927-022-00298-4. PubMed 36045453 ↗
  • Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022 Aug;33(5):2614-2620. doi: 10.1080/09546634.2022.2060924. Epub 2022 Apr 11. PubMed 35385361 ↗
  • Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0. PubMed 35139908 ↗
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17. PubMed 34921355 ↗
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Kivitz AJ, FitzGerald O, Nash P, Pang S, Azevedo VF, Wang C, Takiya L. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clin Rheumatol. 2022 Feb;41(2):499-511. doi: 10.1007/s10067-021-05894-2. Epub 2021 Sep 12. PubMed 34510295 ↗
  • de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Fleischmann R, Taylor PC, Azevedo V, Fallon L, Woolcott J, Mease PJ. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open. 2021 Jul;7(2):e001609. doi: 10.1136/rmdopen-2021-001609. PubMed 34226183 ↗
  • Coates LC, Bushmakin AG, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC, Hsu MA, Helliwell PS. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther. 2021 Mar 26;23(1):94. doi: 10.1186/s13075-021-02474-2. PubMed 33766074 ↗
  • Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020 Oct;2(10):543-554. doi: 10.1002/acr2.11166. Epub 2020 Sep 10. PubMed 32910531 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9. PubMed 32006348 ↗
  • Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930. PubMed 31112005 ↗
  • Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4. PubMed 31111255 ↗
  • Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019. PubMed 30713722 ↗
  • Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5. PubMed 30680661 ↗
  • Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9. PubMed 30414064 ↗
  • Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0. PubMed 30373651 ↗
  • Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977. PubMed 29045207 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Apr 2016, 32 months.

Results were first posted in Sep 2017, 1 year 5 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 32 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2013
First posted
Jun 20, 2013
StartActual
Aug 2013
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Sep 15, 2017
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01882439
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 20, 2013
Start date
Aug 2013
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Sep 15, 2017
Last update
Sep 15, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion